BTL's Novel Catheter Shows Promise in Early Atrial Fibrillation Ablation
核心洞察
BTL (搜索) announced successful treatment of initial patients in a first-in-human study using a next-generation catheter for atrial fibrillation (搜索) (AF) ablation.
The catheter system employs pulsed-field ablation (PFA) to enhance the safety, speed, and effectiveness of AF treatments.
Early results from six patients indicate the new catheter is safe, effective, and straightforward, aligning with preclinical study outcomes.
BTL (搜索), a medical device innovator, has announced the successful treatment of the first patients with atrial fibrillation (搜索) (AF) using a next-generation catheter in a first-in-human feasibility study. The new catheter system is designed to improve AF ablation through pulsed-field ablation (PFA).
The clinical trial is being led by Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, NY; Dr. Petr Neuzil, Chief of Cardiology at Na Homolce Hospital (搜索), Prague; and Dr. Štěpán Havránek, Head of Cardiac Electrophysiology at the General University Hospital in Prague.
Technology and Design
BTL (搜索)'s technology features single-shot PVI for efficient pulmonary vein isolation and a design that facilitates placement in diverse anatomies. The ablation system targets essential areas beyond PVI using a single device and incorporates high-density intracardiac signal acquisition for precise treatment. It supports various ablation sizes, from linear lesions to area ablations.
Expert Opinions
Dr. Vivek Reddy commented, "Our initial clinical results using the BTL (搜索) catheter are very promising, and I look forward to the continued progress of clinical testing."
Dr. Petr Neuzil stated, "The first six patients we treated with the Easy Pulz™ catheter at Homolka Hospital, together with my colleague Professor Vivek Reddy, had safe, effective, and straightforward procedures. These early results suggest that this new pulse field technology is very promising, with a lot of potential to make treatments easier and better for our patients."